References

1. Boch, J. (2011). TALEs of genome targeting. Nature Biotechnology , 29 (2), pp. 135-136.
2. Boch, J., & al. (2009). Breaking the Code of DNA Binding Specificity of TAL-Type III Effectors. Science (326), pp. 1509-1512.
3. Boch, J., & al. (2009). Breaking the Code of DNA Binding Specificity of TAL-Type III Effectors. Science (326), pp. 1509-1512.
4. Camarero, J. A., Fushman, D., Cowburn, D., & Muir, T. W. (2001). Peptide Chemical Ligation Inside Living Cells: In Vivo Generation of a Circular Protein Domain. Bioorganic & Medicinal Chemistry , pp. 2479-2484.
5. Camarero, J. A., Fushman, D., Cowburn, D., & Muir, T. W. (2001). Peptide Chemical Ligation Inside Living Cells: In Vivo Generation of a Circular Protein Domain. Bioorganic & Medicinal Chemistry , pp. 2479-2484.
6. Evans, T. C., Benner, J., & Xu, M.-Q. (1999). The Cyclization and Polymerisation of Bacterially Expressed Proteins Using Modified Self-splicing Inteins. The Journal of Biological Chemistry , 274 (26), pp. 18359-18363.
7. Geissler, R., & al. (2011). Transcriptional Activators of Human Genes with Programmable DNA-Specificity. PLOS one.
8. Heidelberg, i. T. (2014). The Ring of Fire. Retrieved 10 13, 2016, from CIRCULARIZATION - Transforming an enzyme into a ring of fire: https://2014.igem.org/Team:Heidelberg/Toolbox/Circularization
9. Hirschler, B. (2016, May). Second baby gets Cellectis "designer" cells to clear leukemia. Retrieved 10 13, 2016, from Reuters: http://www.reuters.com/article/us-health-celltherapy-idUSKCN0XX1F7
10. Iwai, H., Lingel, A., & Plückthun, A. (2001). Cyclic Green Fluorescent Protein Produced in Vivo Using an Artificially Split PI-PfuI Intein from Pyrococcus furiosus. The Journal of Biological Chemistry , 276 (19), pp. 16548-16554.
11. Lonzaric, J., & al. (2016). Locked and proteolysis-based transcription activator-like effector (TALE) regulation. Nucleic Acids Research , 44 (3), pp. 1471-1481.
12. Miller, J., & al. (2011). A TALE nuclease architecture for efficient genome editing. Nature Biotechnology , 29 (2), pp. 143-148.
13. Muir, T. W. (2003). Semisynthesis of proteins by expressed protein ligation. Annu. Rev. Biochem. (72), pp. 249-289.
14. Office, G.-I. P. (2015, September). World first use of gene-edited immune cells to treat ‘incurable’ leukemia. Retrieved 10 13, 2016, from Great Ormond Street Hospital for Children: http://www.gosh.nhs.uk/news/press-releases/2015-press-release-archive/world-first-use-gene-edited-immune-cells-treat-incurable-leukaemia
15. Qasim, W., & al. (2015). First Clinical Application of Talen Engineered Universal CAR19 T Cells in B-ALL. Blood , 126 (23), p. 2046.
16. Specter, M. (2016, August). How the DNA Revolution Is Changing Us. Retrieved 10 13, 2016, from National Geographic: http://www.nationalgeographic.com/magazine/2016/08/dna-crispr-gene-editing-science-ethics/
17. Streubel, J., & al. (2013). TALEs - Proteine mit programmierbarer DNA-Bindespezifität. BIOspektrum , 2013 (4), pp. 370-373.
18. Tavassoli, A., & Benkovic, S. J. (2007). Split-intein mediated circular ligation use in the synthesis of cyclic peptide libraries in E. coli. Nature Protocols , 2 (5), pp. 1126-1133.
19. Weber, E., & al. (2011). Assembly of Designer TAL Effectors by Golden Gate Cloning. PloS One , 6 (5).
20. Williams, N. K. (2002). In Vivo Protein Cyclization Promoted by a Circularly Permuted Synechocystis sp. PCC6803 DnaB Mini-intein. The Journal of Biological Chemistry , 227 (10), pp. 7790-7798.
21. Wood, D. W., & Camarero, J. A. (2014). Intein Applications: From Protein Purification and Labeling to Metabolic Control Methods. The Journal of Biological Chemistry , 289 (21), pp. 14512-14519.